K-Phos Neutral

Name: K-Phos Neutral

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include numbness or tingly feeling, muscle stiffness or limp feeling, loss of movement, confusion, heavy feeling in your legs, irregular heartbeats, or feeling like you might pass out.

This medicine side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • severe or ongoing diarrhea;

  • seizures (convulsion);

  • shortness of breath; or

  • signs of a kidney problem--little or no urinating; painful or difficult urination; swelling in your feet or ankles; feeling tired or short of breath.

Common side effects may include:

  • nausea, vomiting, stomach pain, diarrhea;

  • bone or joint pain;

  • headache, dizziness, tired feeling;

  • muscle pain or weakness;

  • increased thirst; or

  • numbness or tingly feeling.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

K-Phos Neutral Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Incidence not known
  • Bone pain
  • convulsions
  • decreased urine output
  • dizziness
  • fast or irregular heartbeat
  • headache
  • joint pain
  • mental confusion
  • muscle cramps
  • numbness or tingling around the lips
  • numbness, tingling, pain, or weakness of the hands or feet
  • shortness of breath
  • swelling of the feet or lower legs
  • troubled breathing
  • unusual thirst
  • unusual tiredness or weakness
  • unusual weight gain
  • weakness or heaviness of the legs

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known
  • Diarrhea
  • nausea
  • stomach pain
  • vomiting

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Uses of K-Phos Neutral

  • It is used to treat or prevent low phosphate levels.

What are some things I need to know or do while I take K-Phos Neutral?

  • Tell all of your health care providers that you take this medicine. This includes your doctors, nurses, pharmacists, and dentists.
  • Have blood work checked as you have been told by the doctor. Talk with the doctor.
  • If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.
  • If you have kidney stones, you may pass old stones when K-Phos Neutral is started. Talk with your doctor.
  • Do not take antacids that have aluminum, magnesium, or calcium in them with this medicine.
  • Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using K-Phos Neutral while you are pregnant.
  • Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.

What are some other side effects of K-Phos Neutral?

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

  • Belly pain.
  • Upset stomach or throwing up.
  • Loose stools (diarrhea).

These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch.

K-PHOS Neutral Description

Each tablet contains 852 mg dibasic sodium phosphate anhydrous, 155 mg monobasic potassium phosphate, and the equivalent of 130 mg monobasic sodium phosphate monohydrate. Each tablet yields approximately 250 mg of phosphorus, 298 mg of sodium (13.0 mEq) and 45 mg of potassium (1.1 mEq). The components of K-PHOS® NEUTRAL have the following chemical names and molecular formulae:

Dibasic Sodium Phosphate, Anhydrous
Molecular Formula: Na2HPO4, Molecular Weight: 141.96.

Monobasic Potassium Phosphate
Molecular Formula: KH2PO4, Molecular Weight: 136.09.

Monobasic Sodium Phosphate, Monohydrate
Molecular Formula:NaH2PO4.H2O, Molecular Weight: 137.98.

Inactive Ingredients: Lactose monohydrate, povidone, white coating (hydroxypropyl methylcellulose, titanium dioxide, maltodextrin, triacetin, glycerol triacetate, polyethylene glycol, sodium citrate, and stearic acid), sodium starch glycolate, and magnesium stearate.

Contraindications

This product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

Precautions

General

This product contains potassium and sodium and should be used with caution if regulation of these elements is desired. Occasionally, some individuals may experience a mild laxative effect during the first few days of phosphate therapy. If laxation persists to an unpleasant degree, reduce the daily dosage until this effect subsides or, if necessary, discontinue the use of this product.

Caution should be exercised when prescribing this product in the following conditions: Cardiac disease (particularly in digitalized patients); severe adrenal insufficiency (Addison's disease); acute dehydration; severe renal insufficiency; renal function impairment or chronic renal disease; extensive tissue breakdown (such as severe burns); myotonia congenita; cardiac failure; cirrhosis of the liver or severe hepatic disease; peripheral or pulmonary edema; hypernatremia; hypertension; toxemia of pregnancy; hypoparathyroidism; and acute pancreatitis. Rickets may benefit from phosphate therapy, but caution should be exercised. High serum phosphate levels may increase the incidence of extra-skeletal calcification.

Information for Patients

Patients with kidney stones may pass old stones when phosphate therapy is started and should be warned of this possibility. Patients should be advised to avoid the use of antacids containing aluminum, magnesium, or calcium which may prevent the absorption of phosphate.

Laboratory Tests

Careful monitoring of renal function and serum calcium, phosphorus, potassium and sodium may be required at periodic intervals during phosphate therapy. Other tests may be warranted in some patients, depending on conditions.

Drug Interactions

The use of antacids containing magnesium, aluminum, or calcium in conjunction with phosphate preparations may bind the phosphate and prevent its absorption. Concurrent use of antihypertensives, especially diazoxide, guanethidine, hydralazine, methyldopa, or rauwolfia alkaloid; or corticosteroids, especially mineralocorticoids or corticotropin, with sodium phosphate may result in hypernatremia. Calciumcontaining preparations and/or Vitamin D may antagonize the effects of phosphates in the treatment of hypercalcemia. Potassium-containing medications or potassium-sparingdiuretics may cause hyperkalemia. Patients should have serum potassium level determinations at periodic intervals.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term or reproduction studies in animals or humans have been performed with K-PHOS ® NEUTRAL to evaluate its carcinogenic, mutagenic, or impairment of fertility potential.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with K-PHOS® NEUTRAL. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. This product should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

Pediatric Use

See DOSAGE AND ADMINISTRATION

PRINCIPAL DISPLAY PANEL - 250 mg Tablet Bottle Label

NDC 0486-1125-01

K-PHOS® Neutral
PHOSPHORUS SUPPLEMENT

Each tablet supplies
250 mg of phosphorus

Rx ONLY

100 TABLETS

Beach

K PHOS   NEUTRAL
sodium phosphate, dibasic, anhydrous, potassium phosphate, monobasic, and sodium phosphate, monobasic, monohydrate tablet, coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0486-1125
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Sodium Phosphate, Dibasic, Anhydrous (Phosphate Ion and Sodium Cation) Sodium Phosphate, Dibasic, Anhydrous 852 mg
Potassium Phosphate, Monobasic (Phosphate Ion and Potassium Cation) Potassium Phosphate, Monobasic 155 mg
Sodium Phosphate, Monobasic, Monohydrate (Phosphate Ion and Sodium Cation) Sodium Phosphate, Monobasic, Monohydrate 130 mg
Inactive Ingredients
Ingredient Name Strength
Povidone K29/32  
Lactose Monohydrate  
Sodium Starch Glycolate Type A Potato  
Magnesium Stearate  
Stearic Acid  
Hypromelloses  
Sodium Citrate  
Maltodextrin  
Triacetin  
Titanium Dioxide  
Polyethylene Glycols  
Product Characteristics
Color WHITE Score no score
Shape OVAL Size 19mm
Flavor Imprint Code Beach;11;25
Contains     
Packaging
# Item Code Package Description
1 NDC:0486-1125-01 100 TABLET, COATED in 1 BOTTLE
2 NDC:0486-1125-05 500 TABLET, COATED in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 04/11/1977
Labeler - Beach Productsd, Inc. (032763633)
Establishment
Name Address ID/FEI Operations
Gillette Manufacturing 160356114 MANUFACTURE(0486-1125)
Revised: 10/2014   Beach Productsd, Inc.
(web3)